tbuckley/cabot-search huggingface dataset:
Papal policy, poverty, and AIDS.
Journal: BMJ (1990)

Theatre and ward costs incurred for patients having either hysterectomy or endomnetrial resection for menorrhagia Endometrial Hysterectomy resection Mean theatre time (h) 1-24 0-75 Mean length of stay (days) 10-6 1 Mean cost (£): Theatre time* 253.37 153.25 Central sterile supply department 19.06 11.20 Sutures 20.00 Dressing 0.30 Gloves 4.00 1.00 Glycine 6.93 Syringes 0.14 Double irrigation system 5.00 Suction tubing 0.70 Sterile water 1.20 1.20 Medical assistantt 11.92 Anaesthetic 12.07 9.47 Cost of operation 321.92 188.89Mean ward costs (£)t 1140.67 107.61Total cost (£) 1462.59296.50 *The costs of theatre time (£204.33/hour)are based on an ideal 90% use of scheduled theatre time and incorporate operating time plus the time for induction and reversal of anaesthesia.tCalculated at an hourly rate from the midpoint on the senior house officer pay scale multiplied by the mean theatre time taken to perform hysterectomy.tCalculated at £107.61 a day.
Issue Highlights
Journal: Circulation (2007)

Sleep apnea is associated with obesity, heart failure, hypertension, and atrial fibrillation.Although cause-and-effect relationships are still uncertain for some of these associations, treatment may improve hypertension and heart failure in some patients.Sleep apnea also causes transient bradyarrhythmias attributed to increased vagal tone during apnea but has not been associated with daytime bradyarrhythmias.Garrigue and colleagues performed sleep studies in consecutive patients who had received a pacemaker for bradyarrhythmias or heart failure.They found that more than half of the population had sleep apnea, which was often severe.The correlation with recognized clinical markers for sleep apnea was poor, such that many would not be detected with screening questionnaires.The findings should alert clinicians to the high prevalence of sleep apnea in patients with bradyarrhythmias.Further studies are needed to assess cause, effect, and the impact of therapy.See p 1703.
Medical education in the United States prepared by the staff of the Council on Medical Education
Journal: JAMA (1965)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Aerobic exercise and blood pressure
Authors: A. J. Lewin
Journal: JAMA (1986)

<h3>To the Editor.—</h3> The recent report by Grimm and co-workers<sup>1</sup>of the prognostic importance of white blood cell (WBC) count as an independent predictor of future coronary heart disease raises many interesting questions about the role WBCs, particularly granulocytes, could play in the etiology of atherosclerosis. In addition to the generation of toxic oxidation metabolites injuring endothelial cells as cited by the authors, the possible role of granulocyte proteinases warrants consideration. Granulocytes contain abundant proteolytic enzymes including an elastase, a collagenase, and cathepsin G, a proteinase with chymotrypsinlike substrate specificity. Under normal circumstances these enzymes, when released, are rapidly and irreversibly inhibited by a group of plasma proteins that circulate in large-molar excess over enzyme concentrations. For example, α<sub>1</sub>-proteinase inhibitor, formerly called α<sub>1</sub>-antitrypsin, is present in plasma at concentrations of 20μM or more.<sup>2</sup>However, α<sub>1</sub>-proteinase inhibitor, the principal inhibitor of granulocyte elastase,
The Olympics and sports medicine. Call for papers
Authors: P. B. Fontanarosa
Journal: JAMA (1995)

No athlete is crowned but in the sweat of his brow. St Jerome, c 342-420 In July 1996, more than 10 000 of the world's finest athletes representing nearly 200 nations will compete in the Games of the XXVIth Olympiad in Atlanta, Ga. In recognition of the centennial of the modern Olympic Games, the editors ofThe Journalwill devote an issue to the Olympics and sports medicine. This issue, which will be published to coincide with the 1996 Summer Games, follows previous<i>JAMA</i>Olympics issues published in conjunction with the 1968,<sup>1</sup>1972,<sup>2</sup>1976,<sup>3</sup>and 1984<sup>4</sup>Olympic Games. The modern Olympic motto, Citius, Altius, Fortius ("swifter, higher, stronger"), accurately describes the progressively superior performance accomplished by successive generations of Olympians.<sup>5</sup>In competition during the 1996 Olympic Games, elite athletes will test themselves in supreme physical, mental, and emotional challenges that, for some, undoubtedly will culminate
Two new reports help put nation's No. 1 killer disease challenges into perspective for 1993
Authors: P. Gunby
Journal: JAMA (1993)

AMERICAN HEART Association officials have just issued their 1993<i>Facts</i>and<i>Statistics</i>booklets about heart disease and stroke. But they clearly are looking beyond this year and perhaps beyond this decade. Noting that people who may not appear to be at high risk "account for the vast majority of sudden death victims in absolute numbers, perhaps 80% of the deaths per year," these booklets set a goal of identifying such potential victims. If research can meet this challenge, it is predicted confidently, "it will be possible to devise broader strategies to prevent sudden cardiac arrest." As it is, the association told science reporters at a Monterey, Calif, seminar last week: "About half of all deaths from heart disease are sudden and unexpected, regardless of the underlying disease. Thus, 50% of all deaths due to atherosclerosis of the coronary arteries are sudden, as are 50% of deaths due to degeneration of
THE OPSONIC INDEX IN CERTAIN ACUTE INFECTIOUS DISEASES.
Journal: JAMA (1907)

The study of specific opsonic indices in certain acute infectious diseases appears to give interesting results. Thus it has been found by Wolf<sup>1</sup>and by Macdonald<sup>2</sup>that in pneumonia the pneumococco-opsonic index undergoes definite changes. Both of these investigators found that in the early stages of pneumonia the index is below normal, but at about the time that the crisis occurs in the typical cases the index rises considerably above normal, to which it gradually returns in the uncomplicated instances. In cases rapidly fatal both these observers found the opsonic index to remain below normal. The observations on the index for streptococci in scarlet fever which have been made by Tunnicliff<sup>3</sup>in Chicago, and by Banks<sup>4</sup>in Great Britain, have given analogous results. Both found that in cases of scarlet fever running fairly typical courses the streptococcoopsonic index is below normal during the early febrile period,
poster session 4: vaccines, monoclonal antibodies and other immunotherapies
Authors: Yong Li, Jian Wang, Syed Abbas Rizvi, Paul Cozzi, Michele Madigan, Carl Power, Pamela Russell, Barry Allen, E Song, C Qu, S Rizvi, C Raja, A Morgenstern, C Apostolidis
Journal: Annals of Oncology (2006)
Abnormal expression of MUC1 apomucin and mature MUC1 mucin in biliary epithelial cells in various cystic liver diseases
Authors: M Sasaki
Journal: Hepatology (1996)

MUC1 apomucin is proposed as an “oncofetal” antigen in the biliary system. We surveyed the biliary expression of MUC1 apomucin and mature MUC1 mucin (highly-glycosylated MUC1 apomucin) in hepatic cysts, biliary microhamartomas, and intrahepatic bile ducts in various cystic liver diseases and clarified the relationship between the expression of these mucins and cystogenesis in the liver. The expression of MUC1 apomucin and mature MUC1 mucin were detected immunohistochemically using the monoclonal antibodies DF3 and SM3, and HMFG1, respectively. We surveyed six livers with adult-type polycystic disease (APCD), six with multiple hepatic cysts without polycystic kidney, 11 with solitary hepatic cysts, and 11 “histologically normal” livers. Biliary microhamartomas were frequently found in the former three. MUC1 apomucin was frequently expressed at the luminar surface of the epithelial cells lining cysts and also in biliary microhamartomas, independent of the type of cystic disease. MUC1 apomucin detected by both monoclonal antibodies (MAbs) DF3 and SM3 was also frequently expressed in the intrahepatic bile ducts from polycystic diseases, particularly the adult-type, whereas such expression was rare in the intrahepatic bile ducts in normal livers. Mature MUC1 mucin was expressed on the luminal surface of the epithelial cells lining cysts in approximately half of hepatic cysts studied, but it was infrequently expressed in biliary microhamartomas and almost absent in the intrahepatic bile ducts. The biliary epithelial cells lining hepatic cysts, biliary microhamartomas, the apparently normal intrahepatic bile ducts in APCD, multiple hepatic cysts, and to a lesser degree, solitary hepatic cysts, express abnormal levels MUC1 apomucin. This implies that biliary epithelial cells expressing MUC1 apomucin are related to the whole cystogenetic process in these diseases. In contrast, the expression of mature MUC1 mucin may be related to the late cystogenetic process in these diseases.
Leads from the MMWR. Behavioral risk-factor surveillance in selected states--1985
Journal: JAMA (1986)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Randomized Trial of Warfarin Nomograms
Authors: Robert Zeller
Journal: Annals of Internal Medicine (2004)

Letters16 March 2004Randomized Trial of Warfarin NomogramsRobert Zeller, MDRobert Zeller, MDFrom Winthrop University Hospital, Mineola, NY 11501.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-140-6-200403160-00024 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Kovacs and colleagues (1) recommended a 10-mg warfarin nomogram for outpatient treatment of acute venous thromboembolism as being superior to a 5-mg regimen (1). I should point out that using the INR as measure of efficacy early in the course of therapy may give one false assurance (2). Factor VII is affected early and will prolong the INR. However, lowering levels of factor VII does not prevent thromboembolism. Lowering levels of factor IX and factor X (the next 2 factors to be altered) does, but this takes longer. I note that 3 of Kovacs and colleagues' patients ...References1. Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, Kovacs J, et al . Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med. 2003;138:714-9. [PMID: 12729425] LinkGoogle Scholar2. Deykin D. Warfarin therapy. 1. N Engl J Med. 1970;283:691-4. [PMID: 4916914] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Winthrop University Hospital, Mineola, NY 11501. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoComparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism Michael J. Kovacs , Marc Rodger , David R. Anderson , Beverly Morrow , Gertrude Kells , Judy Kovacs , Eleanor Boyle , and Philip S. Wells Randomized Trial of Warfarin Nomograms Brian F. Gage Randomized Trial of Warfarin Nomograms Robert J. DiDomenico Randomized Trial of Warfarin Nomograms Mark A. Crowther , Linda Harrison , and Jack Hirsh Randomized Trial of Warfarin Nomograms Theodore E. Warkentin Randomized Trial of Warfarin Nomograms Kenneth L. McCall Randomized Trial of Warfarin Nomograms Michael J. Kovacs and Philip S. Wells Randomized Trial of Warfarin Nomograms Gregory M. Peterson and Shane L. Jackson Randomized Trial of Warfarin Nomograms Richard White and William Dager Metrics Cited byA 10 mg warfarin initiation nomogram is safe and effective in outpatients starting oral anticoagulant therapy for venous thromboembolism 16 March 2004Volume 140, Issue 6Page: 489KeywordsInternational normalized ratioLow molecular weight heparinOutpatientsRandomized trialsThromboembolismVenous thromboembolism ePublished: 16 March 2004 Issue Published: 16 March 2004 Copyright & PermissionsCopyright © 2004 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Accurate Determination of Hemoglobin Levels in Daily Practice
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes
Authors: Abigail Aiken, G James, Catherine Aiken
Journal: New England Journal of Medicine (2016)

safe method, accessed misoprostol from local pharmacies or the black market, or visited local underground providers.But accurate data on these choices are difficult to obtain. 5Thus, our data provide a window on how concern about Zika virus infection may have affected the lives of pregnant women in Latin America.Models that were developed by the World Health Organization predict that 3 million to 4 million persons across the Americas (including North America, Central America, South America, and the Caribbean) will contract Zika virus infection through early 2017, and the virus will inevitably spread to other countries where access to safe abortion is restricted.Official information and advice about potential exposure to the Zika virus should be accompanied by efforts to ensure that all reproductive choices are safe, legal, and accessible.
Archives of Internal Medicine, Chicago
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Why I Favor Compulsory Health Insurance
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of Magnetic Field Exposure on Anchorage-Independent Growth of a Promoter-Sensitive Mouse Epidermal Cell Line (JB6)
Authors: John E. Snawder, Richard M. Edwards, David L. Conover, W. Gregory Lotz
Journal: Environmental Health Perspectives (1999)

The anchorage-independent growth of mouse epidermal cells (JB6) exposed to 60-Hz magnetic fields (MF) was investigated. Promotion-responsive JB6 cells were suspended in agar (10(4)cells/plate) and exposed continuously to 0.10 or 0.96 mT, 60-Hz magnetic fields for 10-14 days, with or without concurrent treatment with the tumor promoter tetradecanoylphorbol acetate (TPA). Exposures to MF were conducted in a manner such that the experimenter was blind to the treatment group of the cells. At the end of the exposure period, the anchorage-independent growth of JB6 cells on soft agar was examined by counting the number of colonies larger than 60 microm (minimum of 60 cells). The use of a combined treatment of the cells with both MF and TPA was to provide an internal positive control to estimate the success of the assay and to allow evaluation of co-promotion. Statistical analysis was performed by a randomized block design analysis of variance to examine both the effect of TPA treatment (alone and in combination with MF exposure) and the effect of intra-assay variability. Transformation frequency of JB6 cells displayed a dose-dependent response to increasing concentrations of TPA. Coexposure of cells to both TPA and 0.10 or 0.96 mT, 60-Hz MF did not result in any differences in transformation frequency for any TPA concentrations tested (0-1 ng/ml). These data indicate that exposure to a 0.10 or 0.96 mT, 60-Hz MF does not act as a promoter or co-promoter in promotion-sensitive JB6 cell anchorage-independent growth.
Chronic bundle-branch block. Clinical significance and management
Authors: J. H. McAnulty
Journal: JAMA (1981)

IT HAS been of concern that bundle-branch block is a precursor of complete heart block. The concept of the distal conduction system being composed of three discrete pathways is one reason for this concern. The bundle branches connect the atrioventricular node to the ventricle. Although this distal conduction system is a syncytium, it can be divided into three major fascicles: the right bundle and the two portions of the left bundle, the anterior fascicle, and the posterior fascicle. Block of one of these fascicles, unifascicular block, can be recognized as either right bundle-branch block, left anterior fascicular block (left-axis deviation of at least —30 degrees with initial R waves in leads II, III, aV<sub>f</sub>, and Q wave in lead I, aV<sub>l</sub>), or left posterior fascicular block (right axis deviation of +105 degrees or greater, with Q waves in II, III, aV<sub>f</sub>, and initial R waves in I,
Response
Authors: S. E. KROWN
Journal: JNCI Journal of the National Cancer Institute (1988)

Journal Article Response Get access SUSAN E. KROWN SUSAN E. KROWN Memorial Sloan-Kettering, Cancer CenterNew York, New York 10021 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 12, 17 August 1988, Pages 974–975, https://doi.org/10.1093/jnci/80.12.974-a Published: 17 August 1988